Violich Capital Management Inc. Trims Position in Becton, Dickinson and Company $BDX

Violich Capital Management Inc. lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 20.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,214 shares of the medical instruments supplier’s stock after selling 4,300 shares during the quarter. Violich Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $2,965,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in BDX. GQG Partners LLC purchased a new position in Becton, Dickinson and Company during the 1st quarter valued at about $689,833,000. Vanguard Group Inc. grew its holdings in Becton, Dickinson and Company by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after buying an additional 1,259,750 shares in the last quarter. Nuveen LLC purchased a new position in Becton, Dickinson and Company during the 1st quarter valued at about $211,097,000. Kingstone Capital Partners Texas LLC purchased a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $155,080,000. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock worth $1,567,654,000 after purchasing an additional 667,957 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 2.1%

Shares of BDX opened at $189.20 on Friday. The firm has a market cap of $54.23 billion, a P/E ratio of 34.03, a P/E/G ratio of 1.48 and a beta of 0.25. The stock has a 50 day simple moving average of $190.60 and a two-hundred day simple moving average of $184.63. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.32 billion during the quarter. On average, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a $1.04 dividend. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 1,838 shares of company stock valued at $348,392 in the last ninety days. Insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of several recent analyst reports. Royal Bank Of Canada reissued a “sector perform” rating and set a $211.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Finally, Argus boosted their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $205.40.

Read Our Latest Research Report on Becton, Dickinson and Company

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Recommended Stories

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.